Fig. 7
From: Prenatal muscle development in a mouse model for the secondary dystroglycanopathies
Pax7 positive progenitor cell quantification. a shows double immunolabelling for Pax7 and laminin α2 in the TA, whilst b shows Ki67+ and type IV collagen in the TA. White arrow indicates Pax7+ nuclei laying beneath the basal lamina whilst the yellow arrow shows Pax7+ nuclei outside of the basal lamina (P0). However, many nuclei were in an ambiguous position and so only, the total number of Pax7+ nuclei was counted. These counts expressed as the number of Pax7+ nuclei per fibre showed a significant reduction in the TA at E15.5 and P0 (p = 0.0083 and p = 0.0157, respectively) in the FKRPKD relative to wild type (c). There was however, a significant increase (p = 0.0017) in the number of Ki67 (cell proliferation marker) positive nuclei was observed in the TA of the FKRPKD at E15.5 but not at P0 (d). The proportion of Pax7 positive nuclei that were also expressing MyoD was not significantly different between WT and FKRPKD (e). Immunolabelling for Pax7/MyoD is shown in (f). All immunolabelling was carried out on serial transverse sections